Shopping Cart 0
Cart Subtotal
USD 0

Syntimmune Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Syntimmune Inc (Syntimmune) is a clinical-stage biotechnology company that focuses to develop Fc receptor (FcRn) based antibody therapeutics for the treatment of autoimmune diseases. Its lead pipeline products includes SYNT001, an investigational humanized IgG4 monoclonal antibody that inhibits the interaction of FcRn with IgG and IgG immune complexes by binding FcRn at both neutral and acidic pH levels; and SYNT002 that targets FcRn-albumin interactions to support the release of albumin-bound toxins, and protect organs such as the liver from toxicity. The company is developing its products for the treatment of autoimmune diseases in neurology, dermatology and hematology among others. Syntimmune is headquartered in Boston, Massachusetts, the US.

Syntimmune Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Syntimmune Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Syntimmune Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Syntimmune Raises USD50 Million in Series B Financing 10

Syntimmune Raises USD8 Million in Final Tranche of Series A Financing Round 11

Syntimmune Raises USD10 Million in Second Tranche of Series A Financing Round 12

Syntimmune Raises USD8 Million in Venture Financing 13

Partnerships 14

Applied BioMath Enters into Agreement with Syntimmune 14

Acquisition 15

Alexion Pharma Acquires Syntimmune 15

Syntimmune Inc-Key Competitors 16

Syntimmune Inc-Key Employees 17

Syntimmune Inc-Locations And Subsidiaries 18

Head Office 18

Recent Developments 19

Corporate Communications 19

Jul 09, 2018: Syntimmune Appoints Mario Saltarelli As Chief Medical Officer 19

Apr 25, 2018: Syntimmune Appoints Andrew Cheng to Board of Directors, Bolstering Clinical Development Expertise 20

Jan 03, 2018: Syntimmune Appoints Jean-Paul Kress, M.D., as President and Chief Executive Officer 21

Product Approvals 22

Sep 12, 2018: Syntimmune announces FDA Orphan Drug Designation for SYNT001 in treatment of pemphigus 22

Clinical Trials 23

May 17, 2018: Syntimmune Announces Positive Preliminary Results from Clinical Proof-of-Concept Trial of SYNT001 in Pemphigus Vulgaris and Foliaceus 23

Feb 26, 2018: Syntimmune to Present Clinical Data on Lead Program SYNT001 at Plenary Session of International Investigative Dermatology Conference 24

Nov 01, 2017: Syntimmune Announces Clinical Data from First-in-Human Trial of Lead Candidate SYNT001 25

Mar 20, 2017: Syntimmune Announces Breakthrough Results of FcRn Inhibition Published in PNAS 27

Appendix 28

Methodology 28

About GlobalData 28

Contact Us 28

Disclaimer 28


List Of Figure

List of Figures

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Syntimmune Inc, Pharmaceuticals & Healthcare, Key Facts 2

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Syntimmune Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Syntimmune Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Syntimmune Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Syntimmune Raises USD50 Million in Series B Financing 10

Syntimmune Raises USD8 Million in Final Tranche of Series A Financing Round 11

Syntimmune Raises USD10 Million in Second Tranche of Series A Financing Round 12

Syntimmune Raises USD8 Million in Venture Financing 13

Applied BioMath Enters into Agreement with Syntimmune 14

Alexion Pharma Acquires Syntimmune 15

Syntimmune Inc, Key Competitors 16

Syntimmune Inc, Key Employees 17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Syntimmune Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.